No abstract

IntroductionBrenner tumor of the ovary is a relatively uncommon neoplasm. It constitutes about 1.5% of all ovarian tumors and has a predilection for post-menopausal woman, with a peak of incidence in the fifth decade (1-3).These tumors are mainly asymptomatic and in case of small lesions they may be incidentally detected (2). Conversely non pathognomonic clinical symptoms, like pelvic palpable mass or abdominal pain, occur only for larger tumors (1). No screening tests or markers for MBTS exist. Different pathological variants exist: the benign, borderline and malignant types.The vast majority of these neoplasms is benign, while only 1% is malignant. This latter type is often bilateral, constituted by a mixture of solid and cystic tissues, and represents an aggressive form (4) associated with a poor prognosis (5).Diagnosis is made with histological examination and surgery remains the mainstay of treatment (6).Due to the rarity of this malignancy, there are few cases of metastatic MBT described in literature, most including liver and lung metastases (2), dural metastases (7), subcutaneous (8) and cutaneous (9) metastases. Nevertheless non-unanimous consensus is given on which is the best adjuvant treatment (6).Here we present a case of a malignant Brenner tumor of the ovary which metastasized to brain, lung and liver, concomitant with endometroid adenocarcinoma of the uterus in a 46-year-old woman. Materials and methodsA 46-year-old Caucasian woman presented at our emergency room for abnormal uterine bleeding and a Introduction. Brenner tumor of the ovary represents an uncommon neoplasm. It constitutes about 1.5% of all ovarian tumors with a peak of incidence in the fifth decade. The vast majority of Brenner tumors is benign, while only 1% is malignant and associated with a poor prognosis. Diagnosis could be made only with histological examination, and surgery is the mainstay of treatment.Materials and methods. Brain metastases from malignant Brenner tumor of the ovary: a case report and a literature review

Anal sphincteric continence was better after surgery with a high or low colorectal anastomosis than after coloanal anastomosis.

[No abstract available

The transcription factors involved in epithelial–mesenchymal transition (EMT-TFs) silence the genes expressed in epithelial cells (e.g., E-cadherin) while inducing those typical of mesenchymal cells (e.g., vimentin). The core set of EMT-TFs comprises Zeb1, Zeb2, Snail1, Snail2, and Twist1. To date, information concerning their expression profile and clinical utility during thyroid cancer (TC) progression is still incomplete. We evaluated the EMT-TF, E-cadherin, and vimentin mRNA levels in 95 papillary TC (PTC) and 12 anaplastic TC (ATC) tissues and correlated them with patients’ clinicopathological parameters. Afterwards, we corroborated our findings by analyzing the data provided by a case study of the TGCA network. Compared with normal tissues, the expression of E-cadherin was found reduced in PTC and more strongly in ATC, while the vimentin expression did not vary. Among the EMT-TFs analyzed, Twist1 seems to exert a prominent role in EMT, being significantly associated with a number of PTC high-risk clinicopathological features and upregulated in ATC. Nonetheless, in the multivariate analysis, none of the EMT-TFs displayed a prognostic value. These data suggest that TC progression is characterized by an incomplete EMT and that Twist1 may represent a valuable therapeutic target warranting further investigation for the treatment of more aggressive thyroid cancers.